Takeda Pharmaceutical (NYSE:TAK) Updates FY 2025 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 3.160-3.160 for the period. The company issued revenue guidance of $29.4 billion-$29.4 billion, compared to the consensus revenue estimate of $28.5 billion.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $17.18 on Friday. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $17.25. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. The stock’s 50 day simple moving average is $15.35 and its two-hundred day simple moving average is $14.79. The company has a market cap of $54.68 billion, a price-to-earnings ratio of 214.79 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.44. The firm had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. As a group, equities analysts anticipate that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TAK. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Takeda Pharmaceutical during the third quarter worth $74,000. Larson Financial Group LLC raised its position in Takeda Pharmaceutical by 43.7% in the 3rd quarter. Larson Financial Group LLC now owns 7,823 shares of the company’s stock valued at $115,000 after purchasing an additional 2,379 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Takeda Pharmaceutical during the second quarter worth $174,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical by 1,652.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 11,845 shares of the company’s stock worth $183,000 after buying an additional 11,169 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.